BackCodex DNA Overview

Codex DNA Total Liabilities

Codex DNA's total liabilities is $21M.

Get informed when a big investor buys or sells

+ Follow
Total Liabilities
$20.86M
↓ 64.36% YoYΔ $-37.68M vs prior year quarter

Peer trimmed avg / median

Loading

Codex DNA Total Liabilities History

Loading

Codex DNA vs. peers: Total Liabilities Comparison

Loading

Codex DNA Total Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Codex DNA (DNAY) FAQ

Codex DNA (DNAY) currently reports a total liabilities of $21M as of September 2024. That compares with $59M in the prior-year period — down 64.4% year over year. Use the charts on this page to explore Codex DNA's total liabilities history and peer comparisons.

Codex DNA's total liabilities decreased from $59M to $21M — a 64.4% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Codex DNA reported $21M in total liabilities as of September 2024. That compares with $59M in the prior-year period — down 64.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $21M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Codex DNA, and consider following DNAY for alerts when major investors trade the stock.

Codex DNA is classified in the Healthcare sector. On total liabilities, it currently shows $21M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DNAY with unrelated industries.